Table 2 Dosage and application form of concomitant VA treatment during ICM therapy
VA treatment | Number of patients |
|---|---|
VA, n (%) | 9 (56.3) |
 Abnobaviscum, n (%) | 7 (43.8) |
  Abnobaviscum Fraxini, 0.2 mg, s.c., n (%) | 1 (6.3) |
  Abnobaviscum Fraxini, 20 mg, i.v., n (%) | 1 (6.3) |
  Abnobaviscum Fraxini, 40 mg, i.v., n (%) | 1 (6.3) |
  Abnobaviscum Fraxini, 60 mg, i.v., n (%) | 1 (6.3) |
  Abnobaviscum Fraxini, 20–60 mg, i.v., n (%) | 1 (6.3) |
   Abnobaviscum Amygdali, 0.2 mg, s.c. /Abnobaviscum Fraxini, 20–40 mg, i.v., n (%) | 2 (12.5) |
 Helixor P, 200 mg, i.v., n (%) | 1 (6.3) |
 Iscador Qu, 5 mg, s.c., n (%) | 1 (6.3) |
No VA, n (%) | 7 (56.3) |